Compare EFC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFC | ATAI |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | 2021 |
| Metric | EFC | ATAI |
|---|---|---|
| Price | $13.81 | $3.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $14.46 | $14.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.2M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 11.27% | N/A |
| EPS Growth | ★ 1.22 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $329,815,000.00 | $3,018,000.00 |
| Revenue This Year | N/A | $943.83 |
| Revenue Next Year | $8.81 | N/A |
| P/E Ratio | $10.39 | ★ N/A |
| Revenue Growth | 13.84 | ★ 811.78 |
| 52 Week Low | $11.12 | $1.15 |
| 52 Week High | $14.40 | $6.75 |
| Indicator | EFC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.06 | 41.30 |
| Support Level | $13.54 | $3.88 |
| Resistance Level | $13.79 | $4.33 |
| Average True Range (ATR) | 0.15 | 0.23 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 79.52 | 15.82 |
Ellington Financial Inc is a specialty finance company. Its primary investment objective is to generate attractive, risk-adjusted total returns for its shareholders by making investments. The company has two reportable segments; The Investment Portfolio Segment is focused on investing in a diverse array of financial assets, including residential and commercial mortgage loans, residential mortgage-backed securities, non-mortgage- and mortgage-related derivatives, debt and equity investments in loan origination companies, and other strategic investments, and The Longbridge Segment is focused on the origination and servicing of reverse mortgage loans. it acquires reverse mortgage loans both through its origination activities and through secondary market purchases.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.